Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Nov 23, 2015

We wish to inform you that the subscription period for new shares in Lytix Biopharma has opened, with gross proceeds of NOK 50-100 million. The proceeds will be used to fund further clinical development of its lead product candidate, LTX-315, currently in Phase I/II combination trials with startup in 2016.

Subscription period: 19 November 2015 until 10 December 2015 at 16:30 (CET)
Subscription price:   Will be determined through book building
Conditional grant:    Around 11 December 2015
Settlement:             Around 7 January 2016

Please contact Arctic Securities (manager and financial adviser for the share issue) for more information: ivar.landgraff@arctic.com

Read article in Finansavisen about the share issue (only in Norwegian)